Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
69.46
+0.86 (1.25%)
At close: May 29, 2025, 4:00 PM
69.35
-0.11 (-0.16%)
After-hours: May 29, 2025, 7:59 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.09B DKK in the quarter ending March 31, 2025, with 19.49% growth. This brings the company's revenue in the last twelve months to 303.14B, up 24.11% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
303.14B DKK
Revenue Growth
+24.11%
P/S Ratio
6.95
Revenue / Employee
3,919,133 DKK
Employees
77,349
Market Cap
305.07B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Abbott Laboratories | 42.34B |
NVO News
- 1 day ago - Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track - WSJ
- 1 day ago - Novo Nordisk's Buy Scenario Is Supported By Quantitative Evidence - Seeking Alpha
- 2 days ago - Weight-loss drugs like Ozempic and Wegovy continue to be in high demand—and expensive. Are prices likely to come down soon? - WSJ
- 4 days ago - Is Novo Nordisk Immune To President Trump's Drug Price Plans - Seeking Alpha
- 4 days ago - Should everyone be taking drugs like Ozempic? Drugs in the GLP-1-category show promise for a growing list of health conditions - WSJ
- 6 days ago - Novo Nordisk's High Risk/Reward Proposition: 129% Rally Or 65% Drop? - Benzinga
- 7 days ago - Novo Nordisk offers Wegovy for $199 for first month to new cash-paying customers - Reuters
- 7 days ago - New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect - PRNewsWire